I think it's approximately the amount of money they talk about for the entire process. That's going from a university laboratory up to a biotech company. You need to have a lot of pre-clinical trials, safety, and clearance in the United States with the FDA. It has its own agenda about things that need to be done before a compound can actually be given to a human as part of a clinical study. I could get accurate figures on this, if the committee would like, from the American model.
On June 8th, 2010. See this statement in context.